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Introduction: Questions remain regarding differences in
nodal evaluation and upstaging between thoracotomy
(open) and video-assisted thoracic surgery (VATS) ap-
proaches to lobectomy for early-stage lung cancer. Potential
differences in nodal staging based on operative approach
remain the ﬁnal signiﬁcant barrier to widespread adoption
of VATS lobectomy. The current study examines differences
in nodal staging between open and VATS lobectomy.
Methods: The National Cancer Data Base was queried for
patients with clinical stage T2N0M0 or lower lung cancer
who underwent lobectomy in 2010–2011. Propensity score
matching was performed to compare the rate of nodal
upstaging in VATS with that in open approaches. Additional
subgroup analysis was performed to assess whether rates
of upstaging differed by speciﬁc clinical setting.
Results: A total of 16,983 lobectomies were analyzed; 4935
(29.1%) were performed using VATS. Nodal upstaging was
more frequent in the open group (12.8% versus 10.3%;
p < 0.001). In 4437 matched pairs, nodal upstaging
remained more common for open approaches. For a sub-
group of patients who had seven lymph or more nodes
examined, propensity matching revealed that nodal
upstaging remained more common after an open approach
than after VATS (14.0% versus 12.1%; p ¼ 0.03). For pa-
tients who were treated in an academic/research facility,
however, the difference in nodal upstaging between an open
and VATS approach was no longer signiﬁcant (12.2% versus
10.5%, p ¼ 0.08).Journal of Thoracic Oncology Vol. 11 No. 2: 222-233Conclusions: For early-stage lung cancer, nodal upstaging
was observed more frequently with thoracotomy than with
VATS. However, nodal upstaging appears to be affected by
facility type, which may be a surrogate for expertise in
minimally invasive surgical procedures.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
The surgical approach to treatment of lung cancer has
traditionally been thoracotomy. Because of the increased
morbidity associatedwithopenchest surgery (especially in
patientswith lung cancer, who often havemultiplemedical
comorbidities), however, minimally invasive options are
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thoracic surgery (VATS) has been used increasingly as a
minimally invasive approach to lung cancer surgery with
excellent morbidity and mortality rates.1–4 Short-term ad-
vantages of VATS over thoracotomy are well documented:
fewer complications, less pain, improved lung function,
shorter recovery period, and lower acute care costs.3,5–12
VATS is particularly beneﬁcial in elderly patients (older
than 70 years), with fewer complications and shorter
hospital stays than with thoracotomy.5
The long-term efﬁcacy of VATS versus thoracotomy
(open) approaches to lung cancer surgery is uncertain.
Survival after surgery for node-negative lung cancer is
associated with the number of lymph nodes (LNs) evalu-
ated.13,14 Higher numbers of LNs resected provide more
complete staging and reduce the likelihood of missing
metastatic LNs. Research has demonstrated the existence
of greater variability inLNassessmentwithVATS thanwith
thoracotomy.15A critical study from theSociety ofThoracic
Surgeons (STS) General Thoracic SurgeryDatabase (GTSD)
found that an open approach resulted in identiﬁcation of a
greater number of occult LN metastases than did VATS.16
Two recent studies also demonstrated superior LN stag-
ing with thoracotomy than with VATS.17,18 Incomplete LN
evaluation with VATS could compromise survival by leav-
ing residual cancer and limiting staging data, thus affecting
optimal treatment based on accurate staging.
In light of the potential differences between the
completeness of nodal staging and safety of VATS and those
of thoracotomy, a critical gap exists in knowledge regarding
which surgical approach (open versus VATS) is optimal for
treatment early-stage lung cancer from the standpoint of
long-term survival. The current study was designed to
examine differences in nodal staging between open and
VATS lobectomy in a large national, generalizable data set.Methods
Data Collection and Deﬁnition of Study Variables
The National Cancer Data Base (NCDB), an oncology
outcomes database maintained by the American Cancer
Society and the American College of Surgeons, represents
approximately70%ofnewlydiagnosedcancer caseswithin
the United States and comprises more than 30 million his-
torical records collected frommore than 1500 Commission
on Cancer–accredited facilities. The NCDB Participant Use
File 2011was queried for patientswith non–small cell lung
cancer (NSCLC) in clinical stage T2N0M0 or lower who
underwent lobectomy in 2010–2011.
All lung cancerswere stagedusing the seventheditionof
the American Joint Committee on Cancer lung cancer stag-
ing guidelines.19,20 Surgical approach (VATS versus open)
was deﬁned on an intention-to-treat basis; thus, thoraco-
scopy cases converted to open lobectomy were classiﬁedas VATS. The facility type was determined by Commission
on Cancer program accreditation level and based on the
types of services provided and case volume.21 Community
cancer programs treat 100 to 500 cases of cancer per year,
comprehensive community cancer programs treat more
than 500 cancer cases, and academic or research programs
(including National Cancer Institute–designated cancer
centers) treat more than 500 cases of cancer in addition to
providing postgraduate medical education.
Primary outcome variables of interest included 30-day
mortality rate, number of regional LNs examined, regional
LN positivity, American Joint Committee on Cancer path-
ologic nodal status (N stage), readmission within 30 days
of surgical discharge, status of surgical margins, and
length of surgical inpatient stay. Long-term survival data
after 2006 are not available in the NCDB 2011 participant
user ﬁles and were thus not available for inclusion in our
analysis. Cases with an unknown surgical approach,
concomitant cancer diagnoses, palliative care, preopera-
tive radiation, ormissing primary outcome variables were
excluded from the data set. After all inclusion and exclu-
sion criteria were met, 16,983 cases remained available
for analysis (Fig. 1). Approval for the study was exempted
by the Institutional Review Board of Emory University.
Data Analysis and Statistical Methods
All data are presented as mean values with standard
deviations or as counts with percentages. All data are
complete except where noted within the text or in foot-
notes to the tables. Descriptive statistics for each variable
were reported. All statistical testswere two sided,with the
alpha threshold of signiﬁcance set at 0.05. The univariate
association of each covariate with surgical approach and
the categorical outcomes was assessed using the chi-
square test for categorical covariates and analysis of
variance for numerical covariates. The univariate associ-
ation of each covariate with inpatient stay was assessed
using analysis of variance for categorical covariates and
Pearson correlation for numerical covariates.
To reduce the treatment selection bias, a propensity
score matching method was implemented. The propensity
scoreswere estimatedwith a logistic regressionmodel that
predicts surgical approach by all baseline covariates of in-
terest in this study: facility type, sex, race, insurance, in-
come, education, urban versus rural residence, Charlson/
Deyo comorbidity score, year of diagnosis, primary site,
histologic diagnosis, grade, age, and tumor size (cm). Cases
from the two surgical groups were matched to each other
without replacement on the basis of propensity scores by
using a greedy matching algorithm.22 The balance of
covariates between the two treatment groups after
matching was evaluated by calculating the standardized
differences with a value less than 0.10 as the criterion of
sufﬁcient balance23 (see Appendix 1 for propensity score
Figure 1. Summary of patient selection using exclusion
criteria.
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comes were then compared between treatment groups by
using the matched sample. To assess differences and ac-
count for thematched design, McNemar’s test was used for
two-level categorical outcomes, Bowker’s test of symmetry
was used for categorical outcomes with more than two
levels, and a paired t-testwas used for numerical outcomes.
Subgroup analyses were conducted separately for
patients treated in an academic/research program facility
and for those who had at least seven regional LNs exam-
ined. The same propensity score matching as described
earlier was implemented to balance baseline covariates
between the two treatment groups, and outcomes
were compared in the matched sample (see Appendixes 2
and 3). All statistical analysis were conducted usingSAS Version 9.3 (SAS Institute Inc., Cary, NC) and SAS
macros developed by the Biostatistics and Bioinformatics
Shared Resource at the Winship Cancer Institute.24
Results
A total of 16,983 lobectomies were analyzed; 4935
(29.1%) were performed using VATS. Descriptive sta-
tistics of the study cohort are shown in Table 1. Females
accounted for 54.4% of the study cohort, and the average
age was 66.7 ± 10.1 years. Approximately half of all
patients (50.7%) had a Charlson/Deyo comorbidity
score of 1 or higher. Adenocarcinoma was the most
common type of NSCLC resected (10,300 cases, 60.6%).
Mean tumor size was 2.85 ± 2.38 cm; 408 cases (2.4%)
were associated with positive surgical margins. The
mean number of LNs examined was 9.67 ± 7.2, and LN
upstaging occurred in a total of 2049 patients (12.1%).
Thirty-day mortality occurred in 315 patients (1.9%),
and the mean postoperative length of stay was 7.0 ± 6.2
days. A total of 746 patients (4.4%) had an unplanned
readmission within 30 days of surgery.
Demographic characteristics and outcomes based on
surgical approach are summarized in Table 2. Mean age
(66.6 versus 66.8 years), white race (88.2% versus
88.3%), and underlying comorbidity as represented by a
Charlson/Deyo score of 0 (49.3% versus 49.4%) were
similar between the open and VATS approaches (p > 0.1
for all variables). VATS was more likely to be performed
in an academic/research or comprehensive community
cancer program (45.1% and 50% of all VATS, respec-
tively). The open approach was associated with larger
tumors (mean 2.9 versus 2.7 cm). There was no differ-
ence between the two cohorts in terms of the rate of
positive surgical margins. VATS was more likely to result
in a greater number of regional LNs examined (9 LNs,
43.7% versus 38.8%; p < 0.001); however, nodal
upstaging was more frequent in the open group (12.8%
versus 10.3%; p < 0.001). Although the open approach
resulted in longer length of hospital stay (mean 7.4
versus 6.1 days) and a higher 30-day mortality rate
(2.1% versus 1.3%) than did VATS (all p < 0.001), VATS
was more likely to lead to an unplanned 30-day read-
mission (6.95% versus 5.9%; p ¼ 0.014).
Results from the propensity-matched sample are
shown in the Table 3. In 4437 matched pairs, VATS
remained associated with a greater number of regional
LNs examined (mean 10.3 versus 9.7; p < 0.001). Nodal
upstaging remained more common for open approaches
(11.9% versus 10.1%; p ¼ 0.008). Upstaging with thora-
cotomy was more common than with VATS at stage N1,
but not N2, nodal stations. As in the results of univariate
analysis, VATS was associated with a 1.0-day shorter
length of hospital stay (p < 0.001), yet it was still more
likely to result in an unplanned 30-day readmission (5.4%
Table 1. Descriptive Statistics of the Study Patients
(N ¼ 16,983)
Variable Value
Patient demographics
Female sex, n (%) 9253 (54.5)
Mean age (mean ± SD) 66.7 ± 10.1
White race, n (%) 14,854 (88.2)
Charlson/Deyo comorbidity score, n (%)
0 8373 (49.3)
1 6130 (36.1)
2 2480 (14.6)
Operative variables, n (%)
Surgical approach,a n (%)
Thoracotomy (open) 12,048 (70.9)
VATS 4935 (29.1)
Facility type, n (%)
Academic/research program (includes NCI) 5777 (34.0)
Comprehensive community cancer program 9947 (58.6)
Community cancer program/other 1259 (7.4)
Histologic diagnosis, n (%)
Adenocarcinoma 10,300 (60.6)
Squamous cell carcinoma 4359 (25.7)
Other or unknown 2324 (13.7)
Tumor size,b cm (mean ± SD) 2.85 ± 2.38
Surgical margin positive, n (%) 408 (2.4)
No. of regional LNs examined (mean ± SD) 9.67 ± 7.2
No. of regional LNs examined, n (%)
0–3 2562 (15.1)
4–6 3978 (23.40)
7–9 3614 (21.3)
>9 6829 (40.2)
AJCC pathologic N stage
0 14,934 (87.9)
1 1387 (8.2)
2 662 (3.9)
Surgical outcomes
30-day mortality rate, n (%) 315 (1.9)
Postoperative length of stay, d (mean ± SD) 7.0 ± 6.2
Unplanned 30-day readmission, n (%) 746 (4.4)
aFollowing intention-to-treat, cohort includes VATS cases con-
verted to open lobectomy.
bTumor size missing in 24 patients.
VATS, video-assisted thoracic surgery; SD, standard deviation; LNs,
lymph nodes; AJCC, American Joint Committee on Cancer.
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30-day mortality rate dissipated.
For a subgroup of patients who had at least seven
LNs examined (Table 4), propensity matching (n ¼ 2825
per group) revealed that nodal upstaging remained more
common after an open approach than after VATS (14.0%
versus 12.1%; p ¼ 0.03). For patients who were treated
in an academic/research program facility (Table 5),
however, the difference in nodal upstaging during VATS
versus open lobectomy was no longer signiﬁcant (10.5%
versus 12.2%, p ¼ 0.08; n ¼ 2008 per group). This
subgroup analysis also revealed that the difference in
risk for unplanned 30-day readmission between the
VATS and open cohorts was no longer statisticallysigniﬁcant. It is possible that the difference may become
signiﬁcant in a larger study cohort.
Discussion
The results from the current study differ somewhat
fromwhat has previously been published. Our propensity-
matched analysis demonstrates that VATS actually yiel-
ded a higher mean number of overall LNs examined than
did open thoracotomy (10.3 ± 7.7 versus 9.7 ± 7.2; p <
0.001). Although the current study could not extrapolate
why a minimally invasive approach would lead to more
LNs examined, it is possible thatmore LNs are fragmented
during VATS than during thoracotomy. More importantly,
however, this result remained consistent in the subgroup
analyses both for seven or more LNs examined and for
procedures performed in academic/research program,
thus indicating that a minimally invasive approach does
not limit the overall extent of LN dissection.
On the other hand, despite the greater number of LNs
removed when the VATS approach was used, our data
show that overall nodal upstaging remained more com-
mon after use of an open approach (11.9% versus 10.1%;
p ¼ 0.008). It is possible that patients undergoing thora-
cotomy had larger, more central tumors. Although tumor
size is controlled for within the propensity model we
present, the centrality of the tumor is unfortunately not
obtainable from the datawithin the NCDB. Like the results
from the STS GTSD study,16 our data also reveal that the
rate of N1 upstaging remained signiﬁcantly higher after
use of an open approach than after VATS (8.0% versus
6.9%; p ¼ 0.046) and there was no signiﬁcant difference
between the two cohorts from the standpoint of rate of N2
upstaging. Similar results were noted in the subgroup
analysis for patientswho had at least seven LNs examined;
however, the difference between the two groups dissi-
pated when academic/research programs only were
analyzed. These data may be indicative of differences in
surgeons’ training in minimally invasive techniques and/
or the specialty of surgeons at different types of centers.
Lung cancer is the leading cause of cancer mortality in
men and women in the United States, with an estimated
221,200 new cases and 158,040 deaths expected in
2015.25 The advanced stage at which most lung cancers
are ﬁrst seen largely accounts for the poor survival rate of
approximately 15% at 5 years. Chemotherapy and radia-
tion provide only small improvements for advanced dis-
ease26–29; however, resection of early-stage lung cancer is
associated with cure rates of 77% to 92%.30–32 To ensure
appropriate surgical treatment of early-stage NSCLC, an
adequate lymphadenectomy is imperative for properly
staging patients and guiding adjuvant therapy.
Currently, the National Comprehensive Cancer
Network recommends that “N1 and N2 nodal resection
and mapping should be a routine component of lung
Table 2. Demographics and Outcomes by Operative Approach
Operative Approach
Variable Open VATSa p Value
Patient demographics
Female sex, n (%) 6476 (53.8) 2777 (56.3) 0.003b
Age, years (mean ± SD) 66.6 ± 10.2 66.9 ± 9.9 0.157
White race, n (%) 10,540 (88.2) 4314 (88.3) 0.839
Charlson/Deyo comorbidity score, n (%)
0 5935 (49.3) 2438 (49.4) 0.281
1 4322 (35.9) 1808 (36.6)
2þ 1791 (14.9) 689 (14.0)
Operative variables, (%)
Facility type
Academic/research program (includes NCI) 3551 (29.5) 2226 (45.1) <0.001b
Comprehensive community cancer program 7478 (62.1) 2469 (50.0)
Community cancer program/other 1019 (8.5) 240 (4.9)
Histologic diagnosis, (%)
Adenocarcinoma 7164 (59.5) 3136 (63.6) <0.001b
Squamous cell carcinoma 3187 (26.5) 1172 (23.8)
Other
Tumor size, cm (mean ± SD) 2.92 ± 2.5 2.67 ± 2.0 <0.001b
Surgical margin positive, (%) 293 (2.4) 115 (2.33) 0.694
No. regional LNs examined (mean ± SD) 9.44 ± 7.2 10.42 ± 8.14 <0.001b
No. regional LNs examined, (%)
0–3 1876 (15.6) 686 (13.9) <0.001b
4–6 2884 (23.9) 1094 (22.2)
7–9 2616 (21.7) 998 (20.2)
>9 4672 (38.8) 2157 (43.7)
AJCC pathologic N stage
0 10,506 (87.2) 4428 (89.7) <0.001
1 1542 (12.8) 507 (10.3)
Surgical outcomes, (%)
30-day mortality rate, (%) 251 (2.1) 64 (1.3) <0.001b
Postoperative length of stay, d (mean ± SD) 7.35 ± SD 6.13 ± SD <0.001b
Unplanned 30-day readmission, (%) 716 (5.9) 343 (6.95) 0.014b
aFollowing intention-to-treat, cohort includes VATS cases converted to open lobectomy.
bSigniﬁcant.
VATS, video-assisted thoracic surgery; NCI, National Cancer Institute; SD, standard deviation; LNs, lymph nodes.
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sampled or complete LN dissection.”33 Currently, there
are no quality metrics that recommend the minimum
number of LNs that should be resected during surgery for
NSCLC to allow adequate staging and a possible survival
beneﬁt. Further, how to best measure the extent of LN
evaluation—on the basis of number of LNs sampled, LN
stations evaluated, or LN weight—remains uncertain.
Multiple studies in the literature have failed to establish a
survival beneﬁt associated with the number of LNs
examined in VATS versus in open lobectomy for early-
stage lung cancer. In a retrospective propensity-matched
analysis, Lee et al. concluded that although thoracotomy
resulted in a more thorough evaluation of LNs (14.3
versus 11.3 LNs; p ¼ 0.001), VATS lobectomy offered
similar overall and disease-free survival rates.17 Merritt
and colleagues echoed these ﬁndings in their retrospec-
tive single-institution analysis of 129patientswith clinicalstageN0NSCLC; they concluded that althoughmore nodes
were evaluated in the open cohort than in theVATS cohort,
there was no difference in 3-year survival rate.18
A retrospective single-institution study from 201015
that compared the adequacy of LN assessment between
VATS (n ¼ 79) and open (n ¼ 464) approaches demon-
strated that (1) fewer LNs were sampled with VATS than
with thoracotomy (7.4 ± 0.6 versus 8.9± 0.2, respectively;
p¼ 0.029); (2) there was no difference in N1 sampling (5.2
±3.6 versus 4.9±4.2; p¼ 0.592; and (3) fewermediastinal
(N2) nodes were sampled with VATS than with thoracot-
omy (2.5 ± 3.0 versus 3.7 ± 3.3, respectively; p ¼ 0.004).
A more recent study from the STS GTSD sought to
determine the frequency of nodal metastases identiﬁed in
clinically node-negative tumors by open (n ¼ 7137) and
VATS (n ¼ 1024) approaches.16 The authors report that
nodal upstaging was observed in 14.3% of open cases
compared with in 11.6% of VATS cases (p < 0.001).
Table 3. Postoperative Outcomes in Propensity-Matched Samplea
Outcome
Surgical Approach: Open
(N ¼ 4437)
Surgical Approach: VATSb
(N ¼ 4437) p Value
No. lymph nodes examined, n (%) <.001c
0–3 636 (14.3) 621 (14.0)
4–6 1054 (23.8) 991 (22.3)
7–9 1004 (22.6) 898 (20.3)
>9 1743 (39.3) 1927 (43.3)
No. lymph nodes examined (mean ± SD) 9.7 ± 7.2 10.3 ± 7.7 <.001c
Total nodal upstaging, n (%) 529 (11.9) 450 (10.1) 0.008c
N1 upstaging 357 (8.0) 307 (6.9) 0.046c
N2 upstaging 172 (3.9) 143 (3.2) 0.098
Surgical margins positive, n (%) 93 (2.1) 107 (2.4) 0.322
30-day mortality rate, n (%) 69 (1.6) 61 (1.4) 0.483
Postoperative length of stay, d (mean ± SD) 7.2 ± 6.4 6.2 ± 5.8 <0.001c
Unplanned 30-day hospital readmission, n (%) 158 (3.6) 240 (5.4) <0.001c
aThe following covariates have been balanced between the two groups: facility type, sex, race, insurance, income, education, urban versus
rural residence, Charlson/Deyo comorbidity score, year of diagnosis, primary site, histologic diagnosis, grade, age, and tumor size (cm).
bFollowing intention-to-treat, cohort includes VATS cases converted to open lobectomy.
cSigniﬁcant.
VATS, video-assisted thoracic surgery; SD, standard deviation.
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wasmore common in the open group than in theVATS group
(9.3% versus 6.7%; p< 0.001); however, upstaging fromN0
to N2 (mediastinal) was not different (5.0% with an open
approach and 4.9% with VATS; p ¼ 0.52). In a propensity-
matched adjustment, hilar (N1) upstaging remained less
common for VATS (6.8% versus 9%, p ¼ 0.002). The study
concluded that lower ratesofN1upstaging in theVATSgroup
may indicate variability in the completeness of hilar and
peribronchial LN dissection. Moreover, it was noted that the
difference in upstaging disappeared after controlling for
surgeonswhoperformthemajorityof their casesusingVATS.
There are numerous additional studies that demon-
strate similar survival rates for VATS versus open ap-
proaches to NSCLC. A 2009 meta-analysis comparing 21Table 4. Postoperative Outcomes in Propensity-Matched Samp
Outcome
Surgical Appr
(N ¼ 2825)
Number of lymph nodes examined, n (%)
7–9 977 (34.6)
>9 1848 (65.4)
Number lymph nodes examined (mean ± SD) 13.34 ± 7.0
Total nodal upstaging, n (%) 396 (14.0)
N1 upstaging 257 (9.1)
N2 upstaging 139 (4.9)
Surgical margins positive, n (%) 65 (2.3)
30-day mortality rate, n (%) 43 (1.5)
Postoperative length of stay, d (mean ± SD) 7.24 ± 6.6
Unplanned 30-day hospital readmission, n (%) 115 (4.1)
aThe following covariates have been balanced between the two groups
rural residence, Charlson/Deyo comorbidity score, year of diagnosis,
bFollowing intention-to-treat, cohort includes VATS cases converted t
cSigniﬁcant.
VATS, video-assisted thoracic surgery; SD, standard deviation.studies investigating surgical outcomes after VATS
versus after open lobectomy for early-stage NSCLC
concluded that there was no difference in locoregional
recurrence from the standpoint of operative approach;
however, it also reported that VATS appears to result in
reduced systemic recurrence and improved 5-year
mortality rates.12 Three more recent series also
concluded that there was no difference in long-term
survival of lobectomy in patients with NSCLC after
VATS versus after open thoracotomy.34–36
On a ﬁnal interesting note, we found that the rate of
unplanned 30-day readmissionwas higher for patients after
VATS than after open lobectomy. This result has not been
previously published in studies using smaller, academic
center–focused or single-institution retrospective data sets.les in which at Least Seven Lymph Nodes were Examineda
oach: Open Surgical Approach: VATSb
(N ¼ 2825) p Value
0.027c
898 (31.8)
1927 (68.2)
13.95 ± 7.4 0.001c
341 (12.1) 0.031c
222 (7.9) 0.106
119 (4.21) 0.214
63 (2.2) 0.859
39 (1.4) 0.659
6.03 ± 5.8 <0.001c
148 (5.24) 0.08
: facility type, sex, race, insurance, income, education, urban versus
primary site, histologic diagnosis, grade, age, and tumor size (cm).
o open lobectomy.
Table 5. Postoperative Outcomes in Propensity-Matched Sample for Academic/Research Programsa
Outcome, n (%)
Surgical Approach: Open
(N ¼ 2008)
Surgical Approach: VATSb
(N ¼ 2008) p Value
No. lymph nodes examined, n (%) 0.032
0–3 250 (12.5) 207 (10.3)
4–6 403 (20.1) 373 (18.6)
7–9 436 (21.7) 405 (20.2)
>9 919 (45.8) 1,023 (51.0)
Number lymph nodes examined (mean ± SD) 10.71 ± 7.9 11.57 ± 8.4 <0.001c
Total nodal upstaging, n (%) 245 (12.2) 210 (10.5) 0.084
N1 upstaging 170 (8.5) 140 (7.0) 0.077
N2 upstaging 75 (3.7) 70 (3.5) 0.671
Surgical margins positive, n (%) 37 (1.8) 41 (2.0) 0.651
30-day mortality rate, % 29 (1.4) 21 (1.1) 0.258
Postoperative length of stay, d (mean ± SD) 7.29 ± 7.7 5.9 ± 5.5 <0.001c
Unplanned 30-day hospital readmission, (%) 68 (3.4) 92 (4.6) 0.255
aThe following covariates have been balanced between the two groups: facility type, sex, race, insurance, income, education, urban versus
rural residence, Charlson/Deyo comorbidity score, year of diagnosis, primary site, histologic diagnosis, grade, age, and tumor size (cm).
bFollowing intention-to-treat, cohort includes VATS cases converted to open lobectomy.
cSigniﬁcant.
VATS, video-assisted thoracic surgery; SD, standard deviation.
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academic/research center type, the difference in read-
mission rate was no longer signiﬁcant (see Table 5). These
results demonstrate that in a samplemore generalizable to a
national population, surgical outcomes may differ signiﬁ-
cantly across center type, and they serve to support the
hypothesis that center type is a marker for differences in
surgeons’ practice that result in superior patient outcomes.
We acknowledge that the current study has several
limitations. First, it is a retrospective analysis of a
deidentiﬁed data set. Although we used propensity score
matching with the goal of eliminating potential known
confounding variables between the two groups, this study
cannot account for unmeasured confounding. Second, the
lack of long-term survival data for our cohort limits the
ability to conclude whether the differences in nodal
upstaging directly affect overall patient survival. Third, the
NCDB lacks clinical details on patients such as pulmonary
function test results, speciﬁcmedical comorbidities beyond
comorbidity scoring, speciﬁc nodal stations examined, and
centrality of tumor. Fourth, we do not have preoperative
staging data on patients within the cohort. It is likely that
certain patients underwent endobronchial ultrasound,
mediastinoscopy, and/or positron emission tomography
scan that inﬂuenced preoperative clinical staging. Finally,
the database does not contain information on surgeons’
specialty training or the volume of VATS procedures and
open lobectomies at speciﬁc institutions.
Despite the aforementioned limitations, the current
study uses a large generalizable national data set that
contains detailed treatment and staging data. As data
in the NCDB are updated, long-term survival data on
our study cohort will become available and futureinvestigations will focus on the relationship between LN
upstaging and overall survival.
Conclusions
On the basis of these national data, nodal upstaging was
observedmore frequently with open thoracotomy than with
VATS for early-stage lung cancer, even when a similar num-
ber of LNs had been examined. However, nodal upstaging
appears to be affected by facility type,whichmay represent a
surrogate for expertise in minimally invasive surgical pro-
cedures. Standardizedquality assurance of LN stagingduring
VATS lobectomy is needed to achieve the goal of eliminating
differences instagingcomparedwithwhenanopenapproach
is used. An analysis of differences in long-term survival rates
between the VATS and thoracotomy approaches to lobec-
tomy for early-stage lung cancer remains a critical unmet
need in determining optimal treatment for NSCLC and
ensuring that minimally invasive approaches provide tumor
control equivalent to that provided by open approaches.
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February 2016 Nodal Upstaging in Early-Stage Lung Cancer 229Appendix 1. Balance Check in Matched Sample Based on Surgical ApproachSurgical Approach
Covariate Level Statistics
Open
(N ¼ 4437)
Minimally
Invasive
(N ¼ 4437) p Valuea
Standardized
Difference
Facility type Community cancer program/other N (Col%) 208 (4.69) 208 (4.69) 0.999 0.000
Comprehensive community cancer program N (Col%) 2223 (50.1) 2221 (50.06) 0.001
Academic/research program (includes NCI) N (Col%) 2006 (45.21) 2008 (45.26) 0.001
Sex Male N (Col%) 1962 (44.22) 1933 (43.57) 0.535 0.013
Female N (Col%) 2475 (55.78) 2504 (56.43) 0.013
White race No N (Col%) 511 (11.52) 530 (11.95) 0.531 0.013
Yes N (Col%) 3926 (88.48) 3907 (88.05) 0.013
Insurance Not insured N (Col%) 89 (2.01) 90 (2.03) 0.965 0.002
Private insurance N (Col%) 1506 (33.94) 1517 (34.19) 0.005
Govt. insurance N (Col%) 2842 (64.05) 2830 (63.78) 0.006
Income <$30,000 N (Col%) 554 (12.49) 544 (12.26) 0.798 0.007
$30,000–$34,999 N (Col%) 732 (16.5) 751 (16.93) 0.011
$35,000–$45,999 N (Col%) 1179 (26.57) 1207 (27.2) 0.014
$46,000þ N (Col%) 1972 (44.44) 1935 (43.61) 0.017
Education 29% N (Col%) 645 (14.54) 652 (14.69) 0.917 0.004
20%–28.9% N (Col%) 973 (21.93) 963 (21.7) 0.005
14%–19.9% N (Col%) 1112 (25.06) 1137 (25.63) 0.013
<14% N (Col%) 1707 (38.47) 1685 (37.98) 0.010
Urban/rural Metro area N (Col%) 3761 (84.76) 3729 (84.04) 0.271 0.020
Urban N (Col%) 615 (13.86) 629 (14.18) 0.009
Rural N (Col%) 61 (1.37) 79 (1.78) 0.033
Charlson/
Deyo score
0 N (Col%) 2182 (49.18) 2172 (48.95) 0.977 0.005
1 N (Col%) 1621 (36.53) 1629 (36.71) 0.004
2þ N (Col%) 634 (14.29) 636 (14.33) 0.001
Year of diagnosis 2010 N (Col%) 1935 (43.61) 1969 (44.38) 0.467 0.015
2011 N (Col%) 2502 (56.39) 2468 (55.62) 0.015
Primary site C341 left: upper lobe, lung; lingula; apex;
pancoast tumor
N (Col%) 1082 (24.39) 1083 (24.41) 0.880 0.001
C342: middle lobe, lung (right lung only) N (Col%) 311 (7.01) 308 (6.94) 0.003
C343 right: lower lobe, lung; base N (Col%) 795 (17.92) 798 (17.99) 0.002
C343 left: lower lobe, lung; base N (Col%) 685 (15.44) 662 (14.92) 0.014
C348: overlapping lesion of lung N (Col%) 29 (0.65) 20 (0.45) 0.027
C349: lung, NOS; bronchus, NOS N (Col%) 37 (0.83) 39 (0.88) 0.005
C341 right: upper lobe, lung; lingula; apex;
pancoast tumor
N (Col%) 1498 (33.76) 1527 (34.42) 0.014
Histologic diagnosis Adenocarcinomas N (Col%) 2848 (64.19) 2834 (63.87) 0.900 0.007
Adenosquamous carcinomas N (Col%) 108 (2.43) 94 (2.12) 0.021
Large cell carcinomas N (Col%) 92 (2.07) 100 (2.25) 0.012
Other tumors, including but not restricted to,
spindle cell carcinoma, and mucoepidermoid
malignancies
N (Col%) 287 (6.47) 293 (6.6) 0.005
Squamous cell carcinomas N (Col%) 1038 (23.39) 1055 (23.78) 0.009
Unknown histologic diagnosis N (Col%) 64 (1.44) 61 (1.37) 0.006
Grade 1 N (Col%) 830 (18.71) 833 (18.77) 0.968 0.002
2 N (Col%) 2035 (45.86) 2008 (45.26) 0.012
3 N (Col%) 1287 (29.01) 1315 (29.64) 0.014
4 N (Col%) 40 (0.9) 41 (0.92) 0.002
Unknown, high-grade dysplasia N (Col%) 245 (5.52) 240 (5.41) 0.005
Patient age Mean ± SD 66.9 ± 10.02 66.86 ± 9.93 0.856 0.004
Size of
tumor (cm)
Mean ± SD 2.73 ± 1.75 2.67 ± 1.82 0.121 0.033
aThe parametric p value is calculated by analysis of variance for numerical covariate and the chi-square test for categorical covariates.
Govt., government; Col%, column percent; NCI, National Cancer Institute; NOS, not otherwise speciﬁed, SD, standard deviation.
230 Medbery et al Journal of Thoracic Oncology Vol. 11 No. 2Appendix 2. Balance Check of Matched Sample Based on Surgical Approach and Academic
Program OnlySurgical Approach
Covariate Level Statistics
Open
(N ¼ 2008)
Minimally
Invasive
(N ¼ 2008) p Valuea
Standardized
Difference
Sex Male N (Col%) 885 (44.07) 861 (42.88) 0.445 0.024
Female N (Col%) 1123 (55.93) 1147 (57.12) 0.024
White race No N (Col%) 307 (15.29) 308 (15.34) 0.965 0.001
Yes N (Col%) 1701 (84.71) 1700 (84.66) 0.001
Insurance Not insured N (Col%) 26 (1.29) 34 (1.69) 0.566 0.033
Private insurance N (Col%) 708 (35.26) 698 (34.76) 0.010
Govt. insurance N (Col%) 1274 (63.45) 1276 (63.55) 0.002
Income <$30,000 N (Col%) 285 (14.19) 269 (13.4) 0.766 0.023
$30,000–$34,999 N (Col%) 338 (16.83) 332 (16.53) 0.008
$35,000–$45,999 N (Col%) 489 (24.35) 514 (25.6) 0.029
$46,000þ N (Col%) 896 (44.62) 893 (44.47) 0.003
Education 29% N (Col%) 310 (15.44) 307 (15.29) 0.994 0.004
20%–28.9% N (Col%) 425 (21.17) 420 (20.92) 0.006
14%–19.9% N (Col%) 506 (25.2) 512 (25.5) 0.007
<14% N (Col%) 767 (38.2) 769 (38.3) 0.002
Urban/rural Metro area N (Col%) 1710 (85.16) 1704 (84.86) 0.962 0.008
Urban N (Col%) 275 (13.7) 280 (13.94) 0.007
Rural N (Col%) 23 (1.15) 24 (1.2) 0.005
Charlson/Deyo score 0 N (Col%) 1014 (50.5) 1023 (50.95) 0.960 0.009
1 N (Col%) 706 (35.16) 700 (34.86) 0.006
2þ N (Col%) 288 (14.34) 285 (14.19) 0.004
Year of diagnosis 2010 N (Col%) 882 (43.92) 899 (44.77) 0.589 0.017
2011 N (Col%) 1126 (56.08) 1109 (55.23) 0.017
Primary site C341 left: upper lobe, lung;
lingula; apex; pancoast tumor
N (Col%) 508 (25.3) 494 (24.6) 0.706 0.016
C342: middle lobe, lung (right lung only) N (Col%) 129 (6.42) 125 (6.23) 0.008
C343 right: lower lobe, lung; base N (Col%) 351 (17.48) 341 (16.98) 0.013
C343 left: lower lobe, lung; base N (Col%) 249 (12.4) 280 (13.94) 0.046
C348: overlapping lesion of lung N (Col%) 8 (0.4) 4 (0.2) 0.037
C349: lung, NOS; bronchus, NOS N (Col%) 18 (0.9) 21 (1.05) 0.015
C341 right: upper lobe, lung;
lingula; apex; pancoast tumor
N (Col%) 745 (37.1) 743 (37) 0.002
Grade 1 N (Col%) 390 (19.42) 393 (19.57) 0.990 0.004
2 N (Col%) 884 (44.02) 891 (44.37) 0.007
3 N (Col%) 595 (29.63) 591 (29.43) 0.004
4 N (Col%) 12 (0.6) 13 (0.65) 0.006
Unknown, high-grade dysplasia N (Col%) 127 (6.32) 120 (5.98) 0.015
Patient age Mean ± SD 66.29 ± 10.25 66.29 ± 10.06 0.994 0.000
Size of tumor (cm) Mean ± SD 2.67 ± 1.78 2.62 ± 1.63 0.404 0.026
aThe parametric p value is calculated by analysis of variance for numerical covariates and the chi-square test for categorical covariates.
Govt., government; Col%, column percent; NCI, National Cancer Institute; NOS, not otherwise speciﬁed, SD, standard deviation.
February 2016 Nodal Upstaging in Early-Stage Lung Cancer 231Appendix 3. Balance Check of Matched Sample Based on Surgical Approach and LN 7Surgical Approach
Covariate Level Statistics
Open
(N ¼ 2825)
Minimally
Invasive
(N ¼ 2825) p Valuea
Standardized
Difference
Facility type Community cancer program/other N (Col%) 95 (3.36) 113 (4) 0.331 0.034
Comprehensive community cancer program N (Col%) 1321 (46.76) 1284 (45.45) 0.026
Academic/research program (includes NCI) N (Col%) 1409 (49.88) 1428 (50.55) 0.013
Sex Male N (Col%) 1262 (44.67) 1228 (43.47) 0.362 0.024
Female N (Col%) 1563 (55.33) 1597 (56.53) 0.024
White race No N (Col%) 353 (12.5) 348 (12.32) 0.840 0.005
Yes N (Col%) 2472 (87.5) 2477 (87.68) 0.005
Insurance Not insured N (Col%) 49 (1.73) 57 (2.02) 0.679 0.021
Private insurance N (Col%) 987 (34.94) 970 (34.34) 0.013
Govt. insurance N (Col%) 1789 (63.33) 1798 (63.65) 0.007
Income <$30,000 N (Col%) 339 (12) 347 (12.28) 0.834 0.009
$30,000–$34,999 N (Col%) 425 (15.04) 445 (15.75) 0.020
$35,000–$45,999 N (Col%) 792 (28.04) 792 (28.04) 0.000
$46,000þ N (Col%) 1269 (44.92) 1241 (43.93) 0.020
Education 29% N (Col%) 395 (13.98) 414 (14.65) 0.883 0.019
20%–28.9% N (Col%) 601 (21.27) 606 (21.45) 0.004
14%–19.9% N (Col%) 705 (24.96) 701 (24.81) 0.003
<14% N (Col%) 1124 (39.79) 1104 (39.08) 0.014
Urban/rural Metro area N (Col%) 2411 (85.35) 2390 (84.6) 0.737 0.021
Urban N (Col%) 373 (13.2) 392 (13.88) 0.020
Rural N (Col%) 41 (1.45) 43 (1.52) 0.006
Charlson/Deyo score 0 N (Col%) 1445 (51.15) 1436 (50.83) 0.846 0.006
1 N (Col%) 997 (35.29) 991 (35.08) 0.004
2þ N (Col%) 383 (13.56) 398 (14.09) 0.015
Year of diagnosis 2010 N (Col%) 1236 (43.75) 1253 (44.35) 0.649 0.012
2011 N (Col%) 1589 (56.25) 1572 (55.65) 0.012
Primary site C341 left: upper lobe, lung; lingula;
apex; pancoast tumor
N (Col%) 770 (27.26) 749 (26.51) 0.953 0.017
C342: middle lobe, lung (right lung only) N (Col%) 136 (4.81) 133 (4.71) 0.005
C343 right: lower lobe, lung; base N (Col%) 511 (18.09) 495 (17.52) 0.015
C343 left: lower lobe, lung; base N (Col%) 403 (14.27) 422 (14.94) 0.019
C348: overlapping lesion of lung N (Col%) 17 (0.6) 14 (0.5) 0.014
C349: lung, NOS; bronchus, NOS N (Col%) 22 (0.78) 23 (0.81) 0.004
C341 right: upper lobe, lung; lingula;
apex; pancoast tumor
N (Col%) 966 (34.19) 989 (35.01) 0.017
Histologic diagnosis Adenocarcinomas N (Col%) 1822 (64.5) 1827 (64.67) 0.920 0.004
Adenosquamous carcinomas N (Col%) 61 (2.16) 66 (2.34) 0.012
Large cell carcinomas N (Col%) 71 (2.51) 67 (2.37) 0.009
Other tumors, including but not
restricted to, spindle cell carcinoma,
mucoepidermoid malignancies
N (Col%) 146 (5.17) 152 (5.38) 0.010
Squamous cell carcinomas N (Col%) 695 (24.6) 676 (23.93) 0.016
Unknown histologic diagnosis N (Col%) 30 (1.06) 37 (1.31) 0.023
Grade 1 N (Col%) 517 (18.3) 519 (18.37) 0.975 0.002
2 N (Col%) 1320 (46.73) 1305 (46.19) 0.011
3 N (Col%) 833 (29.49) 836 (29.59) 0.002
4 N (Col%) 31 (1.1) 31 (1.1) 0.000
Unknown, high-grade dysplasia N (Col%) 124 (4.39) 134 (4.74) 0.017
Patient age Mean ± SD 66.96 ± 9.89 66.89 ± 9.93 0.804 0.007
Size of tumor (cm) Mean ± SD 2.82 ± 1.71 2.78 ± 2.04 0.455 0.020
aThe parametric p value is calculated by analysis of variance for numerical covariates and the chi-square test for categorical covariates.
Govt., government; Col%, column percent; NCI, National Cancer Institute; NOS, not otherwise speciﬁed, SD, standard deviation.
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